BACK of the BOOK
YEAR IN REVIEW
2017 was the biggest year yet for ASH Clinical News . In our third year of publication , the magazine has :
• covered the latest news from national and international hematologic conferences
• reported on everything from Predatory Publishing to The Pains of Opioid Prescribing in our in-depth Feature articles
• unearthed interesting facts about innovators and mentors in hematology in our Pulling Back the Curtain series
• published provocative editorials and columns from our Editorial Board and contributors
Here , we take a look back at 2017 .
The Year in Clicks
Here are the year ’ s most-accessed articles and videos from ASHClinicalNews . org :
Top 10 Articles
1 . Contract Research Agonizations by Mikkael Sekeres , MD , MS ( June 2017 ) 2 . How I Teach the Coagulation Cascade by Alice Ma , MD ( April 2016 ) 3 . Cartwheels for CAR T-Cell Therapy ? ( January 2017 Annual Meeting Edition ) 4 . FDA Places Clinical Hold on Studies of Allogeneic CAR T-Cell Therapy
( September 21 , 2017 ) 5 . Agent Orange and Hematologic Malignancies : The Fog of War Still Hovers
( May 2017 ) 6 . Advocating for a Return to Common Sense in Clinical Research
( July 2017 Bonus Mid-Year Edition ) 7 . Predatory Publishing : The Dark Side of the Open-Access Movement ( January 2017 ) 8 . Order Matters : The Art and Science of Myeloma Drug Sequencing ( April 2017 ) 9 . FDA Places Holds on Clinical Trials of PD-1 Inhibitor Durvalumab ( November 1 , 2017 ) 10 . From the ASH Annual Meeting : Immunotherapy in AML : Nivolumab Combined with Azacitidine ( January 2017 )
Most Popular Tweets
Here are the most popular Tweets from @ ASHClinicalNews in 2017 .
1 . April 1 To keep things fresh , we ’ ll be experimenting with some new names for groups of # hematologists . What should we call you and your colleagues ?
2 . May 19 Costly CAR Ts : A report from UK ’ s NICE found that # CARTcell therapies will need to carry a $ 649K price tag to be considered cost-effective
3 . June 15 Responding to @ MikkaelSekeres ’ # CROs editorial , 80 + European researchers call for common sense in clinical research
Top 5 Feature Articles
1 . Agent Orange and Hematologic Malignancies : The Fog of War Still Hovers ( May 2017 ) 2 . Order Matters : The Art and Science of Myeloma Drug Sequencing ( April 2017 ) 3 . Drawing First Blood : Should Patients With Myelodysplastic Syndromes Undergo
Transplant ? ( May 2017 ) 4 . It Runs in the Blood ( July 2017 Bonus Mid-Year Edition ) 5 . The Geography of Drug Approvals ( August 2017 )
Top 5 Videos
4 . September 19 The @ US _ FDA approved gemtuzumab ozogamicin for CD33 + # AML - marking the 5th # leukemia therapy approved since August
5 . July 3 Alternative Facts About Alternative Medicines : The @ US _ FDA is cracking down on companies making false claims about anti-cancer products
Eytan M . Stein , MD Noopur Raje , MD Jae Hong Park , MD Richard Stone , MD Mathias Rummel ,
Enasidenib Shows “ Encouraging ” Efficacy in IDH2- Mutated AML
Denosumab Versus ZA for Myeloma- Related Bone Disease
Improving Outcomes , Minimizing Toxicity With CAR T-Cell Therapy in B-Cell ALL
New FLT3 Inhibitor Crenolanib Shows Promise in FLT3- Mutated AML
MD , PhD Bendamustine- Rituximab “ StiL ” Beats R-CHOP for Indolent Lymphomas
ASHClinicalNews . org ASH Clinical News
135